Feasibility of overnight closed-loop control based on hourly blood glucose measurements

Journal of Diabetes Science and Technology

Volumn 6, Issue 4, 2012, Pages 902-909

  Patte, Caroline ^a   Pleus, Stefan ^b   Galley, Paul ^c   Weinert, Stefan ^c   Haug, Cornelia ^b   Freckmann, Guido ^b  

^a Roche Diabetes Care GmbH   (Germany)

^b Institut Für Diabetes Technologie Forschungs und Entwicklungsgesellschaft MbH   (Germany)

^c Roche Diagnostics Operations Inc Roche Diagnostics Indiana   (United States)

Author keywords

Artificial pancreas; Closed loop insulin delivery; Continuous subcutaneous insulin infusion; Overnight control

Indexed keywords

GLUCOSE; INSULIN; ANTIDIABETIC AGENT;

ADULT; ALGORITHM; ARTICLE; ARTIFICIAL PANCREAS; CLINICAL ARTICLE; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MEAL; NIGHT; PATIENT SAFETY; BLOOD; BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG ADMINISTRATION; FOOD INTAKE; INSTRUMENTATION; INSULIN INFUSION; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; TIME;

ADULT; APPETITE REGULATION; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MEALS; MIDDLE AGED; TIME FACTORS;

EID: 84873157050     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600422     Document Type: Article

References (33)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86.
2. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968-83.
3. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-53.
4. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care. 2002;25(3):593-8.
5. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care. 1996;19(4):324-7. (Pubitemid 26115454)
6. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev. 2002;18 Suppl 1:S14-20. (Pubitemid 34411296)
7. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med. 2002;19(9):746-51. (Pubitemid 35013853)
8. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-76. Epub 2008 Sep 8.
9. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29(1):44-50. (Pubitemid 44033429)
10. Deiss D, Bolinder J, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29(12):2730-2. (Pubitemid 44912209)
11. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. An artificial endocrine pancreas. Diabetes. 1974;23(5):389-96.
12. Pfeiffer EF, Thum C, Clemens AH. The artificial beta cell - a continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system). Horm Metab Res. 1974;6(5):339-42.
13. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006;23(1):1-12.
14. Freckmann G, Kalatz B, Pfeiffer B, Hoss U, Haug C. Recent advances in continuous glucose monitoring. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:347-57.
15. Schmidt FJ, Sluiter WJ, Schoonen AJ. Glucose concentration in subcutaneous extracellular space. Diabetes Care. 1993;16(5):695-700. (Pubitemid 23127172)
16. Sternberg F, Meyerhoff C, Mennel FJ, Bischof F, Pfeiffer EF. Subcutaneous glucose concentration in humans. Real estimation and continuous monitoring. Diabetes Care. 1995;18(9):1266-9.
17. Lönnroth P, Jansson PA, Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol. 1987;253(2 Pt 1):E228-31.
18. Nielsen JK, Gravholt CH, Djurhuus CB, Brandt D, Becker J, Heinemann L, Christiansen JS. Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c. J Diabetes Sci Technol. 2007;1(6):857-63.
19. Schoemaker M, Andreis E, Röper J, Kotulla R, Lodwig V, Obermaier K, Stephan P, Reuschling W, Rutschmann M, Schwaninger R, Wittmann U, Rinne H, Kontschieder H, Strohmeier W. The SCGM1 System: subcutaneous continuous glucose monitoring based on microdialysis technique. Diabetes Technol Ther. 2003;5(4):599≠-608.
20. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care. 2010;33(1):121-7. Epub 2009 Oct 21.
21. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934-9. Epub 2008 Feb 5.
22. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De Palma A, Wilinska ME, Acerini CL, Dunger DB. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375(9716):743-51. Epub 2010 Feb 4.
23. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, Orsini Federici M, Pieber TR, Schaller HC, Schaupp L, Vering T, Wilinska ME. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas. 2004;25(4):905-20. (Pubitemid 39121173)
24. Cordingley JJ, Vlasselaers D, Dormand NC, Wouters PJ, Squire SD, Chassin LJ, Wilinska ME, Morgan CJ, Hovorka R, Van den Berghe G. Intensive insulin therapy: enhanced Model Predictive Control algorithm versus standard care. Intensive Care Med. 2009;35(1):123-8. Epub 2008 Jul 26.
25. Heinemann L, Nosek L, Kapitza C, Schweitzer MA, Krinelke L. Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care. 2009;32(8):1437-9. Epub 2009 Jun 1.
26. Buckingham B, Chase HP, Dassau E, Cobry E, Clinton P, Gage V, Caswell K, Wilkinson J, Cameron F, Lee H, Bequette BW, Doyle FJ 3rd. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care. 2010;33(5):1013-7. Epub 2010 Mar 3.
27. Elleri D, Allen JM, Nodale M, Wilinska ME, Acerini CL, Dunger DB, Hovorka R. Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with Type 1 diabetes. Diabet Med. 2010;27(4):480-4.
28. Cengiz E, Swan KL, Tamborlane WV, Steil GM, Steffen AT, Weinzimer SA. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technol Ther. 2009;11(4):207-10.
29. Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33(6):1282-7. Epub 2010 Mar 23.
30. Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D, Kollman C, Nodale M, Murphy HR, Dunger DB, Amiel SA, Heller SR, Wilinska ME, Evans ML. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ. 2011;342:d1855. doi: 10.1136/bmj.d1855.
31. Cameron F, Niemeyer G, Buckingham BA. Probabilistic evolving meal detection and estimation of meal total glucose appearance. J Diabetes Sci Technol. 2009;3(5):1022-0.
32. Percival MW, Bevier WC, Wang Y, Dassau E, Zisser HC, Jovanovič L, Doyle FJ 3rd. Modeling the effects of subcutaneous insulin administration and carbohydrate consumption on blood glucose. J Diabetes Sci Technol. 2010;4(5):1214-28.
33. Dassau E, Bequette BW, Buckingham BA, Doyle FJ 3rd. Detection of a meal using continuous glucose monitoring: implications for an artificial beta-cell. Diabetes Care. 2008;31(2):295-300. Epub 2007 Oct 31.